Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
The president also said he "offered to personally vouch" for Rocky's bail. Sweden, however, does not have a bail system.Politicsread more
CoinShares Chief Strategy Officer Meltem Demirors discusses Facebook's Libra project and its impact on the cryptocurrency market after testifying to the House Financial...Fast Moneyread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
President Donald Trump's executive order on kidney care will be a boon to a transplant diagnostics company, according to Raymond James.
The financial firm has a "Strong Buy" rating on CareDx, a biotech company with a product that can be used to predict whether kidney transplants will be rejected. Raymond James thinks the executive order from the Trump administration will fuel 12-15% annual growth in the number of completed organ transplants.
"We still expect a multiyear tailwind for transplants, and as a result, we are raising our revenue estimates [for CareDx] given an acceleration from the ~5% typical increase in annual kidney transplants," the analysts wrote, saying that the company is a "best in class growth story" in the transplant diagnostic space.
Raymond James also believes the executive order could lead to an increase in heart transplants. The total addressable market for kidney and heart transplant care is currently about $2.6 billion, the analysts wrote.
CareDx has 30% market penetration in heart transplants and 5% in kidney transplants, but its kidney technology is still fairly new, according to Raymond James.
The executive order is aimed at increasing the number of kidney transplants, while also lowering the total spending on kidney care by the federal government. Medicare spends more than $100 billion per year treating kidney disease.
CareDx, which has a market cap of $1.7 billion, was up as much as 2.5% in early trading. It has gained more than 50% so far this year. Raymond James has a price target of $46 per share for the company.